Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta‐Analysis of Clinical Trials
GRAs superiorly reduce ALT levels, MRI-PDFF, and ELF. Resmetirom significantly reduces AST, HDL, and LDL levels, increases MASH resolution without worsening of fibrosis, and offers a more favourable safety profile. Both GRAs and resmetirom significantly increase adiponectin.
Authors
- Hazem Ayesh (ORCID: https://orcid.org/0000-0001-8231-705X)
- Celina R Andonie (ORCID: https://orcid.org/0009-0006-3351-5723)
- Mahmoud Ladadweh
- Alaaeddin Abusalameh
- Ibrahim Ismail
- Tamer Hodrob
Institutions
- Al-Quds University (PS)
- Deaconess Hospital (US)
Publication Details
- Journal
- Endocrinology Diabetes & Metabolism
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1002/edm2.70157
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00